I asked Minerva if Min-101 was effective for anhedonia, here’s their answer:
"I am responding to your emailed question regarding the impact of treatment with MIN-101 on anhedonia. You will note on the attached presentation of data from the Phase IIb trial with MIN-101 that patients who received the 64 milligram dose of the drug experienced statistically significant improvement in their total anhedonia score (slide #16). Patients who received 32 milligrams also improved but not to a statistically significant degree. This presentation was delivered at the Annual Meeting of the American College of Neuropsychopharmacology (ACNP) last December 2016.
We expect to meet with regulatory authorities in the next several months to discuss the design of our Phase III clinical program with MIN-101 and to initiate the next trial in the second half of this year."
I was blessed, my negative symptoms are at low intensity. Unfortunately my cognition seems to be slipping. Hopefully min-101 can deliver when it comes to cognition.
Not quite. Phase 2 of MIN-101 was performed in Russia and Romania (my country). Unfortunately I didn’t know about it until it was to late to enroll. My pdoc would have referred me, I guess, but my parents probably would’ve been against it.